Skip to content
lifestyle.gopreneurs.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 23, 2026
Lilly declares second-quarter 2026 dividend
May 22, 2026
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
May 22, 2026
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 21, 2026
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
May 20, 2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 16, 2026
Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
May 16, 2026
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
April 29, 2026
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
April 28, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
April 17, 2026
←
Previous Page
1
2
3
4
5
6
Next Page
→